AIMLogo.jpg
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
15 sept. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...
AIMLogo.jpg
Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains
14 mai 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, May 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it has entered into a formal collaborative research agreement...
AIMLogo.jpg
Hemispherx Analysis of New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
22 janv. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21,...
AIMLogo.jpg
Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
21 janv. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21,...
AIMLogo.jpg
Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
07 janv. 2014 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...
Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season
16 déc. 2013 08h30 HE | Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new...
FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses
09 déc. 2013 08h00 HE | Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that its Phase 1/2 clinical trial at the University of Alabama...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
26 août 2013 08h00 HE | Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread
20 août 2013 11h21 HE | Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...